Cargando…

Description of the L76V Resistance Protease Mutation in HIV-1 B and “Non-B” Subtypes

OBJECTIVE: To describe the prevalence of the L76V protease inhibitors resistance-associated mutation (PI-RAM) in relation with patients’ characteristics and protease genotypic background in HIV-1 B- and “non-B”-infected patients. METHODS: Frequency of the L76V mutation between 1998 and 2010 was surv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Charpentier, Charlotte, Lambert-Niclot, Sidonie, Alteri, Claudia, Storto, Alexandre, Flandre, Philippe, Svicher, Valentina, Perno, Carlo-Federico, Brun-Vézinet, Françoise, Calvez, Vincent, Marcelin, Anne-Geneviève, Ceccherini-Silberstein, Francesca, Descamps, Diane
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3548776/ https://www.ncbi.nlm.nih.gov/pubmed/23349869 http://dx.doi.org/10.1371/journal.pone.0054381

Ejemplares similares

Selected amino acid mutations in HIV-1 B subtype gp41 are Associated with Specific gp120(V3 )signatures in the regulation of Co-Receptor usage
por: Dimonte, Salvatore, et al.
Publicado: (2011)

Similar Evolution of Cellular HIV-1 DNA Level in Darunavir/Ritonavir Monotherapy versus Triple Therapy in MONOI –ANRS136 Trial over 96 Weeks
por: Lambert-Niclot, Sidonie, et al.
Publicado: (2012)

HIV Replication Is Not Controlled by CD8(+) T Cells during the Acute Phase of the Infection in Humanized Mice
por: Petit, Nicolas Y., et al.
Publicado: (2015)

Scoring Methods for Building Genotypic Scores: An Application to Didanosine Resistance in a Large Derivation Set
por: Houssaini, Allal, et al.
Publicado: (2013)

Prevalence of resistance and HIV-1 protease mutation patterns after failures with fosamprenavir-containing regimens
por: Marcelin, AG, et al.
Publicado: (2010)

Investigation of Super Learner Methodology on HIV-1 Small Sample: Application on Jaguar Trial Data
por: Houssaïni, Allal, et al.
Publicado: (2012)

Less frequent follow-up in routine care than in trials does not impact resistance selection in patients failing DRV/r or ATV/r first line treatment
por: Marcelin, Anne-Genevieve, et al.
Publicado: (2014)

HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc
por: Rodriguez, Christophe, et al.
Publicado: (2015)

The 501Y.V2 SARS-CoV-2 variant has an intermediate viral load between the 501Y.V1 and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients
por: Teyssou, Elisa, et al.
Publicado: (2021)

Evaluation of different analysis pipelines for the detection of HIV-1 minority resistant variants
por: Perrier, Marine, et al.
Publicado: (2018)

Genetic divergence of HIV-1 B subtype in Italy over the years 2003–2016 and impact on CTL escape prevalence
por: Alteri, Claudia, et al.
Publicado: (2018)

The Delta SARS-CoV-2 variant has a higher viral load than the Beta and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients
por: Teyssou, Elisa, et al.
Publicado: (2021)

Darunavir resistance spectrum in darunavir-na#239;ve patients harboring virological failure to antiretroviral therapy
por: Marcelin, AG, et al.
Publicado: (2010)

The Role of HIV Infection in Neurologic Injury
por: Scutari, Rossana, et al.
Publicado: (2017)

INSTI-Based Triple Regimens in Treatment-Naïve HIV-Infected Patients Are Associated With HIV-RNA Viral Load Suppression at Ultralow Levels
por: Lambert-Niclot, Sidonie, et al.
Publicado: (2019)

Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors
por: Malet, Isabelle, et al.
Publicado: (2017)

A Very Low Geno2pheno False Positive Rate Is Associated with Poor Viro-Immunological Response in Drug-Naïve Patients Starting a First-Line HAART
por: Armenia, Daniele, et al.
Publicado: (2014)

HCV Genotypes Are Differently Prone to the Development of Resistance to Linear and Macrocyclic Protease Inhibitors
por: Cento, Valeria, et al.
Publicado: (2012)

Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naïve to the antiretroviral drugs
por: Alteri, Claudia, et al.
Publicado: (2009)

Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B
por: Svicher, Valentina, et al.
Publicado: (2021)

Reply to Das and Berkhout, “How Polypurine Tract Changes in the HIV-1 RNA Genome Can Cause Resistance against the Integrase Inhibitor Dolutegravir”
por: Malet, Isabelle, et al.
Publicado: (2018)

Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates
por: Visseaux, Benoit, et al.
Publicado: (2015)

Role of Baseline HIV-1 DNA Level in Highly-Experienced Patients Receiving Raltegravir, Etravirine and Darunavir/Ritonavir Regimen (ANRS139 TRIO Trial)
por: Charpentier, Charlotte, et al.
Publicado: (2013)

Different Patterns of HIV-1 Replication in MACROPHAGES is Led by Co-Receptor Usage
por: Borrajo, Ana, et al.
Publicado: (2019)

Characterization update of HIV-1 M subtypes diversity and proposal for subtypes A and D sub-subtypes reclassification
por: Désiré, Nathalie, et al.
Publicado: (2018)

Clinical presentation of Covid-19 in health care workers from a French University Hospital
por: Jary, Aude, et al.
Publicado: (2020)

Efficacy of once daily darunavir/ritonavir 800/100 mg in PI/r-experienced HIV-1 infected patients with suppressed HIV-1 replication: the RADAR study
por: Ghosn, J, et al.
Publicado: (2010)

Week 48 efficacy of 900/100 mg daily of darunavir/ritonavir in treatment-experienced HIV-1 patients with virological success: DARDAR study
por: Schneider, L, et al.
Publicado: (2010)

Predictive Value of Liver Enzymes and Inflammatory Biomarkers for the Severity of Liver Fibrosis Stage in HIV/HCV Co-Infected Patients
por: Charpentier, Charlotte, et al.
Publicado: (2013)

In Silico Investigation of the New UK (B.1.1.7) and South African (501Y.V2) SARS-CoV-2 Variants with a Focus at the ACE2–Spike RBD Interface
por: Villoutreix, Bruno O., et al.
Publicado: (2021)

First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2)
por: Matheron, Sophie, et al.
Publicado: (2018)

SARS-CoV-2 Mutations and Variants May Muddle the Sensitivity of COVID-19 Diagnostic Assays
por: Alkhatib, Mohammad, et al.
Publicado: (2022)

In Silico and In Vitro Comparison of HIV-1 Subtypes B and CRF02_AG Integrases Susceptibility to Integrase Strand Transfer Inhibitors
por: Ni, Xiaoju, et al.
Publicado: (2012)

New HIV-1 circulating recombinant form 94: from phylogenetic detection of a large transmission cluster to prevention in the age of geosocial-networking apps in France, 2013 to 2017
por: Wirden, Marc, et al.
Publicado: (2019)

Inhibition of Dual/Mixed Tropic HIV-1 Isolates by CCR5-Inhibitors in Primary Lymphocytes and Macrophages
por: Surdo, Matteo, et al.
Publicado: (2013)

Effects of Amprenavir on HIV-1 Maturation, Production and Infectivity Following Drug Withdrawal in Chronically-Infected Monocytes/Macrophages
por: Borrajo, Ana, et al.
Publicado: (2017)

Decreased Sensitivity of Rapid Antigen Test Is Associated with a Lower Viral Load of Omicron than Delta SARS-CoV-2 Variant
por: Cocherie, Théophile, et al.
Publicado: (2022)

HIV-1 Gag gene mutations, treatment response and drug resistance to protease inhibitors: A systematic review and meta-analysis protocol
por: Nka, Alex Durand, et al.
Publicado: (2021)

An Increase in the Levels of Middle Surface Antigen Characterizes Patients Developing HBV-Driven Liver Cancer Despite Prolonged Virological Suppression
por: Brancaccio, Giuseppina, et al.
Publicado: (2021)

Detection of Gag C-terminal mutations among HIV-1 non-B subtypes in a subset of Cameroonian patients
por: Teto, Georges, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4napaigrvcbargd6r4efgca974